Maria C. Finazzi

Bergamo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Poor Graft Function (PGF) Following In Vivo T Cell-Depleted Allogeneic Stem Cell Transplantation: The Role of Delayed Immune Reconstitution.

Poor Graft Function (PGF) Following In Vivo T Cell-Depleted Allogeneic Stem Cell Transplantation: The Role of Delayed Immune Reconstitution.

Journal: Transplantation and cellular therapy

Published: April 14, 2026

Outcomes of allogeneic hematopoietic stem cell transplantation in patients with blast phase myelofibrosis: molecular signature and intensive chemotherapy matter.

Outcomes of allogeneic hematopoietic stem cell transplantation in patients with blast phase myelofibrosis: molecular signature and intensive chemotherapy matter.

Journal: Clinical and experimental medicine

Published: March 27, 2026

PTCy or ATG for Matched Transplantation in Myelofibrosis.

PTCy or ATG for Matched Transplantation in Myelofibrosis.

Journal: American journal of hematology

Published: January 03, 2026

A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm.

A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm.

Journal: Bone marrow transplantation

Published: September 05, 2025

CMV Reactivations During and After Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.

CMV Reactivations During and After Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.

Journal: Mediterranean journal of hematology and infectious diseases

Published: August 09, 2025

Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.

Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm.

Journal: Haematologica

Published: July 14, 2025

The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis.

The number of additional high molecular risk mutations predicts outcome after hematopoietic stem cell transplantation in primary and secondary myelofibrosis.

Journal: Blood cancer journal

Published: June 24, 2025

The 2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients.

The 2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients.

Journal: American journal of hematology

Published: March 05, 2025

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party.

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party.

Journal: Blood cancer journal

Published: February 26, 2025

Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis.

Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis.

Journal: Blood cancer journal

Published: September 05, 2024

Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry.

Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real-world ERNEST-2 registry.

Journal: HemaSphere

Published: July 26, 2024

Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy.

Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy.

Journal: British journal of haematology

Published: July 24, 2024

Showing 1-12 of 57

Last Updated: 09/26/2026